

SECZYL TABLET

Generic name:	Secnidazole
Composition/Presentation:	SECZYL TABLETS Each tablet contains Secnidazole 500 mg. SECZYL DS TABLETS Each tablet contains Secnidazole 1000 mg Available as 4 Tablets X 10 Blisters
Drug category:	Anti-amoebic/Antiprotozoal drug

MOLECULAR INTRODUCTION

Secnidazole is of Synthetic origin, structurally related to the commonly used 5-nitroimidazoles metronidazole and tinidazole. These drugs share a common spectrum of activity against anaerobic micro-organisms. The Molecular Weight of Secnidazole is 185.20.

INDICATIONS

Secnidazole is primarily indicated in conditions like amoebiasis, giardiasis, trichomoniasis and Bacterial vaginosis.

PHARMACOKINETIC

- Plasma half life is 20 hr.
- Renal Excretion accounts for 50 %
- Is rapidly and completely absorbed after oral administration
- Has a longer terminal elimination half-life (approximately 17 to 29 hours) than commonly used drugs in this class. Secnidazole have a much longer half-life than Metronidazole, allowing single-dose or once daily administration.

DOSAGE

One day treatment: Secnidazole is given 2 gm as a single dose after food.

DRUG INTERACTION

Secnidazole is known to interact with other drugs like

- Cimetidine (HCl)
- Fluorouracil
- Lithium
- Phenobarbitone
- Phenytoin
- Warfarin

These interactions are sometimes beneficial and sometimes may pose threats to life.

SIDE EFFECTS

The severe or irreversible adverse effects include Leucopenia.

The symptomatic adverse reactions produced by Secnidazole are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Abdominal pain, Urticaria, Glossitis, Stomatitis X, Taste disturbances, Paresthesias.

WARNING AND PRECAUTIONS

Alcoholic drinks and alcohol containing medicines should be avoided during secnidazole treatment. Do not administer to subjects with a history of blood dyscrasia.

NOTE

The convenience and ease of administration associated with single-dose therapy, combined with a good tolerability profile, make Secnidazole a suitable option to other single-dose treatments and an attractive alternative to multiple dosage regimens with other drugs in this class.

For further information, please contact:

Market Planning Department



Deurali-Janta Pharmaceuticals Pvt. Ltd.

GPO Box 4239, 355 Hattisar Road, Kamalpokhari, Kathmandu, Nepal.

Tel: 4435167/68/69 E-mail: mplanning@deuralijanta.com Website: www.deuralijanta.com